Pharmaceuticals, Biotechnology and Life Sciences
Destiny Pharma has picked MedPharm to develop new topical formulations of its novel XF-platform compounds, new treatments for dermal and ocular infections which are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR).
Read more
Destiny Pharma’s XF-73 nasal gel formulation has been classified non-irritant, in the second Phase 1 study, which confirms the good safety profile.
Read more
Destiny Pharma’s first of two Phase 1 safety clinical studies of testing XF-73’s potential to cause dermal irritation, as Destiny’s
Read moreDestiny Pharm has consolidate its board with appointing Nick Rodgers as an independent Non-Executive Director with immediate effect.
Read more
FDA has fast tracked Destiny Pharma’s lead clinical candidate exeporfinium chloride (XF-73) for the prevention of post-surgical staphylococcal infections such
Read more
Destiny Pharma said on Friday that its development and commercialisation collaboration agreement with CMS Medical Venture Investment Limited, a wholly
Read more
Destiny Pharma, a clinical stage biotech company focused on the development of new anti-microbial drugs, has appointed Neil Clark as Chief Executive Officer (CEO) and member of the Board of Directors, effective immediately.
Read more